Invivyd (IVVD) Non-Current Assets (2021 - 2025)
Invivyd (IVVD) posted Non-Current Assets of $29.4 million for Q4 2025, little changed on a QoQ basis from $29.4 million in Q3 2025, and up 2.02% year-over-year from $28.8 million in Q4 2024.
Invivyd (IVVD) Non-Current Assets (2021 - 2025) Analysis & Trends
Invivyd's Non-Current Assets history runs 5 years deep, the most recent figure standing at $29.4 million for Q4 2025.
- Quarterly Non-Current Assets rose 2.02% year-over-year to $29.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $116.6 million (up 135.16% YoY) and the FY2025 annual result came in at $29.4 million, up 2.02% from the prior year.
- Non-Current Assets was $29.4 million for Q4 2025 at Invivyd, roughly flat from $29.4 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $29.9 million in Q2 2025 and bottomed at $1.9 million in Q2 2021.
- A 5-year average of $11.2 million and a median of $5.6 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets tumbled 48.47% — and 2025, when it jumped 588.74%.
- Invivyd's Non-Current Assets stood at $3.4 million in 2021, then jumped by 84.91% to $6.2 million in 2022, then tumbled by 31.2% to $4.3 million in 2023, then soared by 570.56% to $28.8 million in 2024, then grew by 2.02% to $29.4 million in 2025.
- Business Quant data shows IVVD's Non-Current Assets at $29.4 million in Q4 2025, $29.4 million in Q3 2025, and $29.9 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 5.83 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 30.30 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1.95 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 285.82 Mn |
| 10 | Invivyd | 104.07 Mn | -122.62 Mn | 16.07 Mn | 29.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 29.42 Mn |
| Sep 30, 2025 | 29.39 Mn |
| Jun 30, 2025 | 29.86 Mn |
| Mar 31, 2025 | 27.92 Mn |
| Dec 31, 2024 | 28.83 Mn |
| Sep 30, 2024 | 10.82 Mn |
| Jun 30, 2024 | 4.34 Mn |
| Mar 31, 2024 | 5.59 Mn |
| Dec 31, 2023 | 4.30 Mn |
| Sep 30, 2023 | 4.81 Mn |
| Jun 30, 2023 | 5.43 Mn |
| Mar 31, 2023 | 5.94 Mn |
| Dec 31, 2022 | 6.25 Mn |
| Sep 30, 2022 | 3.15 Mn |
| Jun 30, 2022 | 3.25 Mn |
| Mar 31, 2022 | 1.97 Mn |
| Dec 31, 2021 | 3.38 Mn |
| Sep 30, 2021 | 6.12 Mn |
| Jun 30, 2021 | 1.93 Mn |